Warren Fiskus

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

56h-index9.2kcitations355works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(137), Acute Myeloid Leukemia Research(117), Histone Deacetylase Inhibitors Research(103), Multiple Myeloma Research and Treatments(59), Ubiquitin and proteasome pathways(48)

Publications355 total

Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor
Blood·2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high‐risk MECOM‐rearranged AML
HemaSphere·2026Open Access
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML
Leukemia·2025· 1 citedOpen Access
Clinical Trial Protocol S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025Open Access
Supplementary Table S1 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025Open Access
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
2025Open Access
Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models
Blood·2025· 1 citedOpen Access
EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)
Blood·2025Open Access
A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder
Blood·2025
Identifying novel 'druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML
Blood·2025Open Access
POSTER: AML-534 Superior Preclinical Efficacy of BRG1/BRM Inhibitor Combined With BET Inhibitor or Decitabine Against MECOM-rearranged (MECOM-r) Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
AML-534: Superior Preclinical Efficacy of BRG1/BRM Inhibitor Combined With BET Inhibitor or Decitabine Against MECOM-rearranged (MECOMr) Acute Myeloid Leukemia (AML)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: AML-559 ASXL1 Mutations in AML Are Associated With a Distinct Epigenetic State That Results in Vulnerabilities to Epigenetic-Targeted Agents
Clinical Lymphoma Myeloma & Leukemia·2025
AML-559: ASXL1 Mutations in AML Are Associated With a Distinct Epigenetic State That Results in Vulnerabilities to Epigenetic-Targeted Agents
Clinical Lymphoma Myeloma & Leukemia·2025
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase
Blood Advances·2025· 1 citedOpen Access
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1
Blood Neoplasia·2025Open Access
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Blood Cancer Journal·2025Open Access
Abstract 451: Superior preclinical efficacy of BRG1/BRM inhibitor combined with BET inhibitor or decitabine against MECOM-rearranged AML
Cancer Research·2025· 1 cited
Abstract 6825: Novel therapeutic strategies targeting MECOM rearranged AMLs discovered by unbiased drug screen
Cancer Research·2025
Abstract 444: ASXL1 mutations in AML are associated with a distinct epigenetic state that results in vulnerabilities to epigenetic-targeted agents
Cancer Research·2025· 1 cited
page 1 of 18Next →

Frequent Co-authors

Kapil N. Bhalla(45), Peter Atadja(16), Rekha Rao(15), Purva Bali(10), Cristian Coarfa(10), Kimal Rajapakshe(9), Christopher P. Mill(9), Ramesh Balusu(8), Yonghua Yang(7), Dyana T. Saenz(7), Tapan M. Kadia(7), Kyungsoo Ha(7), Michael Pranpat(6), Maria E. Balasis(6), Fei Guo(6), Jianguang Chen(6), Santhana G.T. Devaraj(6), Baohua Sun(6), Joseph D. Khoury(6), Kathy Rocha(5)